|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of US Patent 11,998,604 (United States): Platinum-Related Ototoxicity Reduction with Aqueous-Anhydrous Sodium Thiosulfate + Boric Acid
US 11,998,604 is a method-of-treatment patent focused on reducing platinum agent–associated ototoxicity in cancer patients. Claim scope is tightly anchored to (i) aqueous anhydrous sodium thiosulfate at about 0.5 M, (ii) about 0.004 M boric acid, and (iii) defined pH windows (broad 5 to 9.5; narrower 6.5 to 8.9; tight 8.6 to 8.8). Dependent claims then narrow to formulation pH/additives (HCl, NaOH), pediatric subpopulations, specific pediatric cancers, and administration timing and infusion parameters in cisplatin dosing contexts. Enforcement risk for generic or alternative products centers on whether a competitor’s regimen uses the same critical concentration/pH system and similar timing for ototoxicity mitigation without loss of platinum antitumor effect.
What are the key claim limitations in US Patent 11,998,604 for reducing ototoxicity from platinum chemotherapy?
Featured snippet answer: The independent claim requires administering a pharmaceutical composition containing aqueous anhydrous sodium thiosulfate at ~0.5 M plus ~0.004 M boric acid to a human patient receiving a platinum-based chemotherapy to reduce ototoxicity.
Independent claim 1: core technical “must-haves”
Claim 1 requires all of the following in combination:
-
Clinical setting
- Human patient receiving a platinum-based chemotherapeutic for a cancer sensitive to the platinum-based chemotherapeutic.
- Objective is reducing ototoxicity.
-
Therapeutic composition
- A pharmaceutical composition comprising:
- aqueous anhydrous sodium thiosulfate
- at about 0.5 M concentration
- and about 0.004 M boric acid.
-
Administration
- An “administering an effective amount” construct.
- The claim is not specific on dose mass or volume in the portion you provided, but it is specific on concentration system and composition composition.
Claim architecture implications
- This is not a composition claim framed as “a formulation,” but a method claim where the infringement hook is the act of administering the specified composition under the specified clinical context.
- The most infringement-sensitive elements are the 0.5 M sodium thiosulfate and 0.004 M boric acid concentration, plus the fact of platinum chemotherapy exposure for a sensitive cancer and the purpose/effect of reducing ototoxicity.
Dependent claims 2–6: formulation adjusters and pH tightening
- Claim 2: composition further comprises hydrochloric acid.
- Claim 3: composition further comprises sodium hydroxide.
- Claim 4: composition pH between about 5 and about 9.5.
- Claim 5: pH between about 6.5 and about 8.9.
- Claim 6: pH between about 8.6 and about 8.8 (tight window, high design-point risk).
Design implication
- If a competitor uses the same sodium thiosulfate/boric acid system but runs outside these pH bands, literal infringement may be avoided. If it stays within one of these bands, infringement risk rises substantially.
Dependent claims 7–13: pediatric narrowing + pediatric-specific pH variants
- Claim 7: pediatric patient.
- Claim 8: pediatric patient is ≤5 years.
- Claims 9–13: introduce the same HCl/NaOH and pH windows for the pediatric context.
Design implication
- Even if an adult regimen could potentially avoid claim 7, a product tested or marketed specifically for pediatric ototoxicity reduction increases exposure to these dependent claims.
Dependent claims 14–17: cisplatin administration timing and infusion mechanics
- Claim 14: platinum-based chemotherapeutic is cisplatin.
- Claim 15: cisplatin administered as an infusion over 1 to 6 hours.
- Claim 16: sodium thiosulfate/boric acid composition administered about 6 hours after completion of cisplatin infusion.
- Claim 17: composition administered as an infusion over about 15 minutes.
Timing and infusion parameters are typically the hardest to work around
- This set creates a method “window” that is narrower than the general independent claim.
- If a competitor replicates the chemistry but changes timing (not “about 6 hours” or infusion duration), it may fall outside claim 16/17 while still potentially risking claim 1 depending on how “effective amount” is interpreted and how “about” is read.
Dependent claims 18–26: pediatric oncology target classes
- Claim 18: hepatoblastoma.
- Claim 19: medulloblastoma.
- Claim 20: neuroblastoma.
- Claim 21: osteosarcoma.
- Claim 22: localized cancer.
- Claim 23: disseminated cancer.
- Claim 24: germ cell tumor.
- Claim 25: testicular cancer (germ cell subset).
- Claim 26: ovarian cancer (germ cell subset).
Design implication
- These claims broaden geographic infringement relevance across pediatric indications. If any clinical program or label for pediatric platinum-induced ototoxicity reduction includes these cancers, exposure to dependent claims 18–26 increases.
How strong is the patent estate for US 11,998,604 given its concentration and pH-defined claim boundaries?
Featured snippet answer: Strength is driven by chemistry-specific concentration requirements (0.5 M sodium thiosulfate and 0.004 M boric acid) and a tight pH band (8.6–8.8), plus an administration-timing dependent branch for cisplatin (about 6 hours post-infusion, ~15-minute infusion).
High-strength “hard points”
- Exact concentration anchors
- ~0.5 M sodium thiosulfate.
- ~0.004 M boric acid.
- pH gating
- Very broad pH coverage exists (5 to 9.5), but the existence of the tight window (8.6 to 8.8) indicates a designed formulation specification.
- Timing/mechanics gating (cisplatin)
- “About 6 hours after completion” and “about 15 minutes infusion” are practical clinic parameters and tend to be determinative for method infringement analyses.
Potential vulnerability surfaces
- Breadth on “effective amount”
- The claim does not specify a numeric mg/kg or volume, which can widen the interpretive surface.
- Role of “about”
- Both concentration and timing use “about,” which can expand infringement range depending on prosecution history and expert claim construction.
- Clinical proof issues
- If litigation requires proving “reducing ototoxicity” as a functional requirement, evidentiary arguments can arise. Method claims of this style often rely on administration for the purpose described.
Litigation leverage likely rests on formulation replication
For business decisions (licensing, worksharing, IV protocol design, or design-around):
- A competitor must decide whether it can avoid one of the hard points:
- alter thiosulfate concentration materially away from 0.5 M,
- remove or adjust boric acid below/away from 0.004 M,
- operate outside the pH bands (especially 8.6–8.8),
- or change administration timing so it is not “about 6 hours” after cisplatin completion and not “about 15 minutes.”
What is the scope for adult vs pediatric infringement under US 11,998,604?
Featured snippet answer: Claim 1 covers any human patient receiving platinum chemotherapy; claims 7–13 add a pediatric constraint and further tighten pH/additives for that subgroup.
Adult
- Infringement path: satisfy claim 1 by administering the specified composition system to a human on platinum therapy with the goal of ototoxicity reduction.
- No adult-specific dependent limitations are listed in your claim set beyond cisplatin/timing claims (14–17).
Pediatric
- Infringement path: claims 7–13 require pediatric status and optionally ≤5 years.
- Additional pediatric dependent limitations tie cancers and dissemination status (18–26).
Market risk assessment framing
- Any clinical adoption in pediatrics (especially ≤5) for platinum-induced ototoxicity mitigation substantially increases claim coverage because it triggers a cluster of dependent claims tied to pH/HCl/NaOH and oncology subtypes.
Which cisplatin-related dosing and infusion timelines are claimed in US 11,998,604?
Featured snippet answer: Cisplatin infusion over 1–6 hours, followed by thiosulfate/boric acid infusion about 6 hours after completion over about 15 minutes.
Timing chain (claims 15–17)
- Cisplatin infusion duration: 1 to 6 hours
- Ototoxicity-reduction infusion start: about 6 hours after cisplatin infusion completion
- Ototoxicity-reduction infusion duration: about 15 minutes
Practical protocol design implications
- If a competitor’s regimen uses a substantially different interval (e.g., several hours earlier/later) or changes the thiosulfate/boric infusion duration, it may avoid dependent claims 16/17.
- However, dependent claims do not replace independent claim 1. If claim 1 remains met (chemistry + effective administration to platinum-treated patients), it is still a threat.
What cancers and pediatric subpopulations are covered by dependent claims 18–26?
Featured snippet answer: The pediatric claim set covers specific oncology indications including hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, localized or disseminated cancer, and germ cell tumors including testicular and ovarian cancer.
Covered pediatric oncology terms
- Hepatoblastoma (18)
- Medulloblastoma (19)
- Neuroblastoma (20)
- Osteosarcoma (21)
- Localized cancer (22)
- Disseminated cancer (23)
- Germ cell tumor (24)
- Testicular cancer (25)
- Ovarian cancer (26)
Indication inference
- The list suggests the patent is built around a pediatric platinum chemo ecosystem rather than a single tumor type.
- For freedom-to-operate in pediatrics, analysis must map any clinical program’s tumor inclusion criteria to these dependent claim terms.
How does the claim wording “aqueous anhydrous sodium thiosulfate” affect formulation design and potential design-around strategies?
Featured snippet answer: The phrase indicates a product concept where sodium thiosulfate is handled to preserve an “anhydrous” form within an aqueous composition, with the claim anchored to a specific final concentration of about 0.5 M.
Why this matters
- “Anhydrous” can be used to distinguish from hydrated forms (for example, pentahydrate) that could change molar amount, osmolarity, stability, and buffering needs.
- The claim does not merely require “sodium thiosulfate”; it requires aqueous anhydrous sodium thiosulfate at the stated concentration.
Design-around pressure points
- Using a hydrated salt form could be an attempt to avoid “anhydrous,” but this depends on claim construction and whether equivalence arguments succeed.
- The more reliable design-around typically targets:
- sodium thiosulfate molarity,
- boric acid molarity,
- and pH windows.
What formulations are implicated by US 11,998,604 pH-dependent claims (4–6 and 11–13)?
Featured snippet answer: The claims define multiple pH bands for the same chemistry system, including a broad band (5 to 9.5), an intermediate band (6.5 to 8.9), and a tight formulation band (8.6 to 8.8). HCl and NaOH appear as pH adjusters.
pH bands in the claim set
- General composition pH:
- 5 to 9.5 (claim 4)
- 6.5 to 8.9 (claim 5)
- 8.6 to 8.8 (claim 6)
- Pediatric composition pH:
- same band logic (claims 11–13)
Adjuncts
- HCl is expressly listed as an optional component (claims 2 and 9).
- NaOH is expressly listed as an optional component (claims 3 and 10).
Operational takeaway
- If a product uses the same sodium thiosulfate/boric acid concentrations but adjusts pH outside 5–9.5, it may avoid the dependent pH claims. But claim 1 does not include a pH limitation, so avoiding dependent pH claims alone may not provide full protection against claim 1.
What patent “battlefield” does this claims set create for Paragraph IV and biosimilar-style challenges?
Featured snippet answer: The patent is method-of-use for an ototoxicity-reduction regimen, so the key competitive threat is copying the chemistry system and clinical protocol. Paragraph IV and generic challenges are less direct unless an ANDA is framed around the same administration regimen and formulation composition.
Generic/ANDA scenario risk
- A generic product replicating the formulation chemistry (0.5 M sodium thiosulfate, 0.004 M boric acid) and used in the same platinum ototoxicity reduction protocol could be within claim 1.
- If timing and infusion match (claims 14–17), additional dependent claim exposure rises.
Biosimilar-like risk is not the primary frame
- The product is a small-molecule/infusate regimen (not a biologic). “Biosimilar” terms are generally inapposite unless a biologic delivery system is involved, which is not present in these claims.
Litigation leverage
- In dispute, the contested points are likely:
- final solution composition (molarities),
- pH in the accepted measurement window,
- administration timing relative to cisplatin completion,
- and indication population (pediatric <=5; tumor types).
Key Takeaways
- US 11,998,604 claim 1 is anchored to a specific chemistry system: aqueous anhydrous sodium thiosulfate at about 0.5 M plus boric acid at about 0.004 M to reduce platinum-associated ototoxicity.
- Dependent claims tighten product operations via pH bands (5–9.5; 6.5–8.9; tight 8.6–8.8), optional pH adjusters (HCl, NaOH), and pediatric constraints (including ≤5 years).
- Cisplatin protocol timing is explicitly claimed: cisplatin infusion over 1–6 hours, then ototoxicity composition infusion about 6 hours after completion for about 15 minutes.
- Pediatric oncology scope is broad within dependent claims 18–26, increasing infringement risk if a competitive product is used in those pediatric tumor settings.
- Design-around efforts must target concentration and protocol elements, not just dosing semantics, because pH and timing-dependent claims sit on top of an independent chemistry-plus-use claim.
FAQs
-
Does claim 1 require a specific cisplatin timing window?
No. Claim 1 is not timing-limited; timing is added in dependent claims 14–17.
-
If a competitor changes pH outside 8.6–8.8, does it avoid infringement?
It may avoid the tight pH dependent claim 6 (and pediatric equivalents), but claim 1 has no pH limitation in the provided wording.
-
Is the patent limited to cisplatin or does it cover other platinum chemotherapies?
Claim 1 covers platinum-based chemotherapeutics generally; cisplatin is specified in dependent claim 14.
-
Which dependent claims create the greatest protocol-specific infringement risk?
The cisplatin timing and infusion duration limitations in claims 16 and 17.
-
Does the pediatric branch cover only certain tumor types?
It covers tumor types listed in dependent claims 18–26, but it also includes broader pediatric categories via localized vs disseminated cancer (claims 22–23) and germ cell tumors (claims 24–26).
References
- United States Patent 11,998,604 (claim text provided in prompt).
More… ↓
⤷ Start Trial
|
